Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, July 20, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Patrick Trucchio Reiterated (VIR) at Strong Buy and Held Target at $100 on, Jul 20th, 2023
Patrick Trucchio of HC Wainwright & Co., Reiterated "Vir Biotechnology, Inc." (VIR) at Strong Buy and Held Target at $100 on, Jul 20th, 2023.
Patrick has made no other calls on VIR in the last 4 months.
There is 1 other peer that has a rating on VIR. Out of the 1 peers that are also analyzing VIR, all agrees with Patrick's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Michelle Gilson of "Morgan Stanley" Maintained at Hold with Increased Target to $27 on, Tuesday, April 4th, 2023
